UCB S.A.
UCB
Classifica tra le azioni
#494
UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in... UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in Brussels, Belgium, focuses on developing innovative solutions for individuals living with neurological and immunological diseases. Its diverse commercialized portfolio includes Cimzia, targeting inflammatory TNF-mediated conditions such as Crohn's disease, various forms of spondyloarthritis, rheumatoid arthritis, and psoriasis. For epilepsy management, UCB offers Vimpat, Keppra, and Briviact, along with Nayzilam, an intranasal rescue treatment for seizure clusters. Neupro is available for Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal address allergy symptoms. Other key products include Evenity for osteoporosis in postmenopausal women, and BIMZELX, which treats psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. The company also provides dapirolizumab pegol for systemic lupus erythematosus. UCB's robust development pipeline features candidates like rozanolixizumab, aimed at myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Beyond its proprietary drug development, UCB also conducts contract manufacturing. The company engages in significant collaborations with entities such as Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. UCB's global footprint extends across numerous countries, including the United States, Japan, China, Belgium, and a broad presence throughout Europe, encompassing Germany, Spain, France, Italy, the United Kingdom, and Ireland.
Prezzo delle azioni
$258.70
Ultima sincronizzazione: 2026-10-20
Capitalizzazione di mercato
$49.32B
Variazione (1 giorno)
6.29%
Variazione (1 anno)
-12.78%
Paese
BE
Scambia UCB S.A. (UCB)
Categoria
Healthcare
Ricavi di UCB S.A. (UCB)
Ricavi nel Jun 2026 TTM: $10.11B
Secondo gli ultimi rapporti finanziari di UCB S.A., i ricavi attuali dell'azienda (TTM) sono pari a $10.11B. Nel 2023, l'azienda ha registrato ricavi di $5.81B una diminuzione rispetto a i ricavi dell'anno 2022, che erano pari a $5.92B. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per UCB S.A. da 2002 a 2026
Ricavi alla fine di ogni anno
| Anno | Ricavi | Cambia |
|---|---|---|
| 2026 (TTM) | $10.11B | 57.94% |
| 2024 | $6.40B | 10.26% |
| 2023 | $5.81B | -1.89% |
| 2022 | $5.92B | -9.92% |
| 2021 | $6.57B | 0.88% |
| 2020 | $6.51B | 18.13% |
| 2019 | $5.51B | 3.56% |
| 2018 | $5.32B | -0.85% |
| 2017 | $5.37B | 23.03% |
| 2016 | $4.36B | 3.68% |
| 2015 | $4.21B | 4.02% |
| 2014 | $4.05B | -6.09% |
| 2013 | $4.31B | -5.66% |
| 2012 | $4.57B | 8.68% |
| 2011 | $4.20B | -2.33% |
| 2010 | $4.30B | -3.70% |
| 2009 | $4.47B | -10.97% |
| 2008 | $5.02B | -5.32% |
| 2007 | $5.30B | 59.66% |
| 2006 | $3.32B | 20.02% |
| 2005 | $2.77B | -42.28% |
| 2004 | $4.79B | 14.36% |
| 2003 | $4.19B | -29.19% |
| 2002 | $5.92B | 0.00% |
Ricavi di aziende simili o concorrenti
| Azienda | Ricavi | Differenza nei ricavi | Il paese |
|---|---|---|---|
| $12.62B | 24.86% |
US
|
|
| $2.23B | -77.96% |
US
|
|
| $15.74B | 55.72% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | -40.45% |
NL
|
